Control of the heparosan N-deacetylation leads to an improved bioengineered heparin
The production of the anticoagulant drug heparin from non-animal sources has a number of advantages over the current commercial production of heparin. These advantages include better source material availability, improved quality control, and reduced concerns about animal virus or prion impurities. A bioengineered heparin would have to be chemically and biologically equivalent to be substituted for animal-sourced heparin as a pharmaceutical. In an effort to produce bioengineered heparin that more closely resembles pharmaceutical heparin, we have investigated a key step in the process involving the N-deacetylation of heparosan. The extent of N-deacetylation directly affects the N-acetyl/N-sulfo ratio in bioengineered heparin and also impacts its molecular weight. Previous studies have demonstrated that the presence and quantity of N-acetylglucosamine in the nascent glycosaminoglycan chain, serving as the substrate for the subsequent enzymatic modifications (C5 epimerization and O-sulfonation), can impact the action of these enzymes and, thus, the content and distribution of iduronic acid and O-sulfo groups. In this study, we control the N-deacetylation of heparosan to produce a bioengineered heparin with an N-acetyl/N-sulfo ratio and molecular weight that is similar to animal-sourced pharmaceutical heparin. The structural composition and anticoagulant activity of the resultant bioengineered heparin was extensively characterized and compared to pharmaceutical heparin obtained from porcine intestinal mucosa.
KeywordsHeparin Heparosan Porcine intestine Deacetylation
The authors are grateful for funding from the NIH in the form of grant # HL096972 and the support of the Bioengineered Heparin Consortium for supporting this research.
- Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D’Angelo A, Beltrametti C, Damiani M, Andrioli GC, Pugliese R, Iorio A, Brambilla G (1998) Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 339:80–85CrossRefGoogle Scholar
- Gerard N, Pierre B (1961) Process of purifying heparin, and product produced therefrom. US patent #2989438Google Scholar
- Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, Capila I, Lansing JC, Guglieri S, Fraser B, Al-Hakim A, Gunay NS, Zhang ZQ, Robinson L, Buhse L, Nasr M, Woodcock J, Langer R, Venkataraman G, Linhardt RJ, Casu B, Torri G, Sasisekharan R (2008) Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26:669–675CrossRefGoogle Scholar
- Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao GL, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R (2008) Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358:2457–2467CrossRefGoogle Scholar
- Kusche M, Hannesson HH, Lindahl U (1991) Biosynthesis of heparin. Use of Escherichia coli K5 capsular polysaccharide as a model substrate in enzymic polymer-modification reactions. Biochem J 275(Pt 1):151–158Google Scholar
- Linhardt RJ (1991) Heparin: an important drug enters its seventh decade. Chem Ind 2:45–50Google Scholar
- Linhardt RJ, Gunay NS (1999) Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 25(Suppl 3):5–16Google Scholar
- Linhardt RJ, Toida T (1997) Heparin oligosaccharides: new analogues—development and applications. In: Nieforth ZJ, Wa KA (eds) Carbohydrates in drug design. Marcel Dekker, New York, pp 277–341Google Scholar
- Linhardt RJ, Rice KG, Kim YS, Lohse DL, Wang HM, Loganathan D (1988) Mapping and quantification of the major oligosaccharide components of heparin. Biochem J 254:781–787Google Scholar
- Okuyama T, Yoshida K, Sakurai K, Ogura T, Horie K, Tawada A, Hara T (1975) Method of separating and recovering mucopolysaccharides from connective tissue of animals. US patent #3862003Google Scholar
- Vidic H-J (1981) Process for the preparation of heparin. US patent #4283530Google Scholar